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Abstract
Background: Niacin is widely available over the counter (OTC). We sought to determine the
safety of 500 mg immediate release niacin, when healthy individuals use them as directed.
Methods: 51 female and 17 male healthy volunteers (mean age 27 years SD 4.4) participated in a
randomized placebo-controlled blinded trial of a single dose of an OTC, immediate-release niacin
500 mg (n = 33), or a single dose of placebo (n = 35) on an empty stomach. The outcomes
measured were self-reported incidence of flushing and other adverse effects.
Results: 33 volunteers on niacin (100%) and 1 volunteer on placebo (3%) flushed (relative risk 35,
95% confidence interval (CI) 6.8–194.7). Mean time to flushing on niacin was 18.2 min (95% CI:
12.7–23.6); mean duration of flushing was 75.4 min (95% CI: 62.5–88.2). Other adverse effects
occurred commonly in the niacin group: chills (51.5% vs. 0%, P < .0001), generalized pruritus (75%
vs. 0%, P = <.001), gastrointestinal upset (30% vs. 3%, P = .005), and cutaneous tingling (30% vs. 0%,
P = <.001). Six participants did not tolerate the adverse effects of niacin and 3 required medical
attention.
Conclusion: Clinicians counseling patients about niacin should alert patients not only about
flushing but also about gastrointestinal symptoms, the most severe in this study. They should not
trust that patients would receive information about these side effects or their prevention (with
aspirin) from the OTC packet insert.
Background
The popularity and availability of over-the-counter health
products (OTCs) is of concern. Some OTCs, particularly
natural health products, are regarded as agents with min-
imal toxic potential and are therefore not required to pass
the strict authentication processes required of prescription
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drugs [1,2]. Furthermore, surveys suggest that traditional
passive mechanisms of reporting of adverse events are
unreliable [3,4]. Indeed, it is possible that the public's per-
ceptions of safety are related to suboptimal reporting of
adverse reactions [5]. The apparent safety of these agents
may be confirmed by product labels and package inserts
that underplay the potential for harm.
Niacin (an OTC vitamin B3 or nicotinic acid) has favora-
ble effects on the lipid profile, but more importantly,
there is evidence of its favorable impact on patient impor-
tant outcomes. In the Coronary Drug Project, patients ran-
domized to receive niacin had a decrease in nonfatal
recurrent myocardial infarction and a reduction in all-
cause mortality nine years after termination of the trial
[6]. In other randomized trials, the combination of niacin
and lovastatin reduced cardiovascular risk in patients with
coronary artery disease[7], and the combination of niacin
and simvastatin produced marked clinical and angio-
graphic benefits in these patients[8,9].
Some studies have suggested that the release of prostag-
landin D2 (PGD2) from dermal macrophages probably
mediates the cutaneous flushing following niacin use
[10,11]. In spite of the known and common association
between niacin and flushing and other adverse reactions,
the package labels and inserts may not sufficiently warn
the buyer of over-the-counter immediate release niacin
(Table 1). While minimized by the use of aspirin and ibu-
profen,[12,13] this cutaneous flush, along with other
reversible adverse effects (such as gastrointestinal upset,
pruritus, rash and headache) often leads to discontinua-
tion of therapy [14].
Niacin is widely available over-the-counter and can be
easily purchased in settings where trained healthcare pro-
fessionals are not available to provide advice or warn of
adverse effects. We undertook a randomized trial of
immediate-release niacin in healthy volunteers in order to
document the adverse effects of niacin when taken as
directed by the package label by a healthy individual. In
this study, we evaluated the incidence, duration, tolerabil-
ity and severity of flushing and other adverse effects fol-
lowing the ingestion of 500 mg of immediate release
niacin.
Methods
The institutional review board of the Canadian College of
Naturopathic Medicine approved the protocol, and all
participants gave written informed consent prior to study
inclusion. We adhered to the Declaration of Helsinki dur-
ing all phases of study conduct.
Participants
We recruited healthy volunteers from a student popula-
tion through lecture announcements. To be eligible for
this study, participants should be 20–60 years of age and
be able to comprehend and complete the intake and
informed consent forms. In addition, they should be able
to complete a 12-hour pre-trial fast, to abstain from food,
caffeine, and alcohol during the study, and to avoid all
medications known to influence gastric acid secretion.
Participants with history of liver disease, gout, gastrointes-
tinal disease, diabetes mellitus, and intolerance to niacin
were excluded. Participants did not receive remuneration
for participation.
Study Design
Enrolled participants attended the research center the
morning of the trial. That morning, we blindly allocated
patient pairs to receive niacin or placebo by coin toss. All
study personnel were blind to treatment allocation and
had no way of influencing whether a participant would
receive niacin or placebo. After clocks were synchronized
and placed around the study location, we asked all partic-
Table 1: Warnings & Precautionary Statements of Niacin Supplements from Different Vitamin Companies
Product Warnings & Precautionary Statements
Product 1. 500 mg caplets Niacin may cause flushing, itching or burning sensations of the skin within twenty minutes after administration. 
Individuals with a history of ulcer, gallbladder or liver disease should consult their physician before use.
Product 2. 500 mg tablets Temporary flushing, itching or warming of the skin may occur. Do not use in cases of gout, diabetes, liver dysfunction 
or pregnancy.
Product 3. 500 mg tablets It is important to consult your physician before taking any nicotinic acid product. Do not use in case of pregnancy, 
gout, diabetes, ulcers or liver dysfunction without medical supervision. Temporary flushing, itching or warming of the 
skin may occur.
Product 4. 500 mg tablets May cause mild flushing, itching or burning sensation of the skin within twenty minutes after administration. Those 
individuals with a history of ulcer, gallbladder or liver disease should consult their physician before taking these 
tablets.
Product 5. 500 mg tablets May cause some flushing, itching or burning skin sensations. In case of a history of ulcers, gallbladder or liver disease, 
consult a physician.BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/4
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ipants to ingest the study drug at the same time. Then we
asked them to record time of ingestion of the study medi-
cation, perceived onset and cessation of flushing, to
record other adverse effects noted, and to judge the overall
tolerability of the study drug on a 5-point Likert-type scale
(See Figure 1).
Results form Figure 1
Results form.
Information provided on informed consent sheet (separate sheet):
Niacin Precautions & Possible Side Effects
• Niacin should never be administered to any patient known to be sensitive to this vitamin. 
• Niacin causes the skin to flush. The flush sometimes begins as early as 15 minutes after it is taken orally. The flush causes 
redness and itching, and can be very unpleasant for some people. The redness and itching may extend from the face down to 
the toes. It sometimes takes 2-3 hours for the flush to go away. Some people report nausea, stomach pain/upset, dizziness, 
cold/hot sensations, dry mouth, and other symptoms with the oral intake of niacin.
• Generally, niacin is not dangerous but toxicity (with sustained release formulations) has been reported. The non-sustained 
release form is the only preparation used in this study. In some people niacin can cause liver damage, precipitate gout, induce 
vomiting, upset blood sugar control, and be intolerable.
Results Form
FULL NAME:
AGE:
WEIGHT (In Lbs.):
ETHNICITY:
DOB:
SEX:
TODAY'S DATE:
Brief Instructions: You are not to ask any of the participants if you are flushing. This study is 
designed to be subjective. In other words, you report when you think you are flushing and you 
report when you think the flushing has ameliorated (stopped). Also, remember to fill out the 
tolerability scale as well. 
Time when medication was taken orally: 
Time when cutaneous flushing perceived:
Time when cutaneous flushing perceived to have ameliorated:
Niacin tolerability scale (circle only one answer):
A. No effect
B. Easy to tolerate
C. Mildly unpleasant, but tolerable
D. Unpleasant, and difficult to tolerate
E. Intolerable, and would never take niacin again
Additional descriptive comments:BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/4
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Study drugs
Jamieson laboratories Inc. provided 500-mg immediate
release niacin in a white, oblong, bisect caplet. We inde-
pendently confirmed caplet content using high perform-
ance liquid chromatography. Most over-the-counter
niacin products suggest 500 mg of niacin as a starting
dose. The placebo was matched to the study drug for taste,
color, and size, and contained microcrystalline cellulose,
silicon dioxide, dicalcium phosphate, magnesium stear-
ate, and stearic acid.
Outcome Measures
Our primary outcome was incidence of flushing. Second-
ary outcomes included tolerability, time to onset of flush-
ing, duration of flushing, additional adverse effects and
the total number of serious adverse effects requiring med-
ication for relief. Participants reported duration of flush-
ing when they felt the flushing had discontinued.
Statistical Analyses
Data analysts were not blind to allocation. We estimated
the sample size required to have 90% power to detect a
difference in the incidence of flushing of 90% or greater
between niacin and placebo (alpha = 0.05). We used the
Mantel-Haenszel procedure to compare the proportion of
participants with flushing in both groups, using a two-
tailed P value < .05 as the threshold for significance. Addi-
tionally, we performed linear regression to explore
whether age, gender, weight or ethnicity predicted
tolerability.
Results
Participant flow is illustrated in Figure 2 and participant
characteristics are noted in Table 2. A total of 33 partici-
pants in the niacin group (100%) and one (3%) in the
placebo group reported cutaneous flushing (P < .0001).
The mean time to onset of cutaneous flushing was 18.2
minutes (95% confidence interval 12.7–23.6) and the
mean duration of flushing was 75.4 minutes (95% confi-
dence interval 62.5–88.2) in the niacin arm. The single
patient in the placebo arm flushed 35 minutes after taking
the placebo pill but did not report the duration. Table 3
summarizes participants' tolerability of niacin and
placebo pills. Table 4 outlines the adverse drug reactions
by group.
Three participants (2 female, 1 male) in the niacin group
withdrew from the study because of the severity of adverse
drug reactions. Emergency unblinding of these partici-
pants was necessary. Two of these individuals vomited
and the other had severe stomach cramping and nausea.
These participants were given either antihistamine drugs,
ibuprofen or bismuth salicylate. Additionally, one partic-
ipant required a small amount of food to relieve gastroin-
testinal upset. All participants requiring medical attention
received medical care until they reported returning to nor-
mal health. We did not identify predictors of tolerability
related to age, ethnicity, sex or weight.
Discussion
This randomized placebo-controlled blinded trial of a sin-
gle dose of immediate release niacin demonstrates the
association between OTCs and important adverse effects
(flushing, chills, and gastrointestinal side effects), severe
enough in 9% of these young healthy volunteers to neces-
sitate medical attention. The severity of the adverse effects
and the relative frequency of them following a single dose
of the product could not have been predicted from review-
ing the product information available at the point of
retail.
Our study used random allocation of participants and
blinding to limit bias in the ascertainment of treatment
effects, particularly since participants self-reported the
adverse effects of treatment. We studied young healthy
volunteers instead of older patients with comorbidities, a
group more representative of those likely to use niacin to
treat dyslipidemia. However, the development of intoler-
able side effects in 1 out of 5 young healthy volunteers
likely underestimates the impact of adverse effects among
older patients with comorbidities. Our study is of brief
duration and only ascertained the effect of a single dose of
niacin in a fasting state. Longer-term niacin use has been
associated with liver disease, an outcome that we did not
set out to investigate [15]. Patients may be able to tolerate
niacin's adverse effects with continued use, dose titration,
switch to sustained-release preparations, pre-treatment
with low-dose aspirin, or ingesting niacin with a meal.
Given the findings of our study, clinicians considering
niacin should begin with low-dose or time-released niacin
to determine tolerability. However, while clinicians are
generally aware of these strategies to limit the side effects
of niacin, individuals buying immediate release niacin
over-the-counter may not know how to prevent them.
We know of two other randomized trials specifically stud-
ying the adverse effects of 500 mg immediate-release
niacin and testing the use of aspirin and ibuprofen to pre-
vent them [12,13]. None of those studies used controls
not receiving niacin and, therefore, provide limited infer-
ences as to the true relative risk of adverse effects with
immediate release niacin. Furthermore, they did not set
out to investigate the extent to which aspirin pre-treat-
ment reduced the impact of gastrointestinal side effects,
the most severe and distressing adverse effect in our study.
Clinicians should consider sharing information with their
patients about the relative safety of OTCs. However, when
clinicians turn to the literature to learn about the safety of
OTCs they will find very little reliable evidence [16]. TheBMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/4
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Flow of participants throughout the trial Figure 2
Flow of participants throughout the trial.
Invited for participation (n=120)
Niacin Treatment
(n=33)
Screened and invited for participation (n=78)
Randomized (n=68)
Placebo
(n=35)
Primary endpoints
(n=33)
Duration of flushing 
unavailable with 3 
participants
Primary endpoints
(n=35 )BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/4
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vast majority of information regarding adverse drug
reactions is derived from case reports (30%) [17]. Con-
trolled trials investigating therapy often report adverse
drug reactions yet are often underpowered to provide
robust estimates of the risk for rare but severe adverse drug
reactions [17]. Additionally, not all clinical drug trials
provide data on the frequency of adverse effects nor are
likely to mention this in an abstract [18]. Thus, searching
databases for information on adverse drug reactions has
many limitations [19,20]. The post-marketing voluntary
reporting process is haphazard and unreliable, particu-
larly when physicians do not personally observe these
reactions [21]. In certain situations, consumers, clinicians,
and policymakers could benefit from rigorous trials
Table 2: Study Participants
Niacin (n = 33) Placebo (n = 35)
Age, years, mean (SD) 27.2 (5.23) 26.4 (3.32)
Sex: Male 7 10
Female 26 25
Weight, kg, mean (SD) 64.05 (11.15) 64.7 (11.29)
Ethnicity:
Caucasian 24 24
Black 1 1
Middle Eastern 0 2
Hispanic 1 1
East Asian 5 5
South Asian 2 2
SD, standard deviation
Table 3: Reported tolerability of niacin and placebo
Tolerability, No. (%) Niacin (n = 33) Placebo (n-35)
No effect 0 (0) 34 (97.1)
Easy to tolerate 2 (6.1) 1 (2.9)
Mildly unpleasant, but tolerable 14 (42.4) 0 (0)
Unpleasant, and difficult to tolerate 11 (33.3) 0 (0)
Intolerable, and would never take niacin again 6 (18.2) 0 (0)
Table 4: Adverse events reported
Adverse Event Niacin (n = 33) Placebo (n = 35) P-value
Composite of pruritus (head. neck, extremities or torso): 25 (75%) 0 <0.001
Composite of tingling (head, torso): 10 (30%) 0 <0.001
Unpleasant warmth or flushing: 33 (100%) 1 <0.001
Nausea 10 (30%) 1 (3%) .005
Vomiting 4 (12%) 0 .005
Stomach cramps 2 (6%) 0 NS
Vertigo 4 (12%) 0 .05
Difficult breathing 2 (6%) 0 NS
Chills* 17 (52%) 0 < .0001
Pass stool 3 (9%) 0 NS
Heart palpitations 5 (15%) 0 .0228
Other 4 (12%) 1 (3%) NS
* Chills are defined as shivering accompanied by the sensation of coldness and pallor of the skin.BMC Clinical Pharmacology 2003, 3 http://www.biomedcentral.com/1472-6904/3/4
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designed and powered to detect and characterize common
and acute adverse effects of commonly used medications
(or OTCs). However, in most situations (i.e., when prod-
ucts exhibit rare but severe adverse effects with long-term
use), reliable and precise safety information will remain
simply unattainable.
Our study highlights the trade-off involved in policy deci-
sions to make health products available in retail stores
without mediation of a health professional, such as a
pharmacist. This study suggests potentially important eco-
nomic considerations, not only from widespread unregu-
lated consumption of these products, but also from
resource utilization to treat their adverse effects. For
instance, does the public know to consider safety issues
when buying yet another vitamin? (Niacin is identified as
a vitamin, vitamin B3) It may be possible to implement
regulation, which ensure product labels contain detailed
information regarding potential adverse effects. Further
debate about the public health implications of expanding
the pool of OTCs and keeping natural health products
unregulated is long overdue.
While the adverse effects observed in this trial may be well
known from clinical experiences, it is possible that niacin
would have difficulties passing licensure from a regulatory
body. This study additionally addresses the public percep-
tion that natural health products are natural, and thus
safe. When considering the risk-benefit profile of
common statins to niacin, the stains have evidence of
safety and efficacy above niacin [22,23].
Conclusions
In summary, this study (1) demonstrates the need for ran-
domized trials to inform policy and patient choice about
the safety of OTCs; (2) underscores the adverse public
health impact of OTCs; and (3) likely underestimates the
impact of adverse effects of OTCs in patients with
comorbidities.
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